Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Xetra
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

STADA Arzneimittel AG

+ Add to Watchlist

SAZ:GR

31.805 EUR 0.483 1.50%

As of 09:20:57 ET on 05/29/2015.

Snapshot for STADA Arzneimittel AG (SAZ)

Open: 32.390 Day's Range: 31.705 - 32.475 Volume: 244,877
Previous Close: 32.288 52wk Range: 24.100 - 36.240 1-Yr Rtn: -5.60%

Stock Chart for SAZ

No chart data available.
  • SAZ:GR 31.800
  • 1D
  • 1M
  • 1Y
32.288
Interactive SAZ Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SAZ

Current P/E Ratio (ttm) 37.4588
Estimated P/E(12/2015) 11.5365
Relative P/E vs. DAX 1.9927
Earnings Per Share (EUR) (ttm) 0.8500
Est. EPS (EUR) (12/2015) 2.7530
Est. PEG Ratio 1.5331
Market Cap (M EUR) 1,946.51
Shares Outstanding (M) 61.13
30 Day Average Volume 372,200
Price/Book (mrq) 2.0196
Price/Sale (ttm) 0.9419
Dividend Indicated Gross Yield 2.07%
Cash Dividend (EUR) 0.6600
Dividend Ex-Date 06/04/2015
5 Year Dividend Growth 4.88%
Next Earnings Announcement 08/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SAZ

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for SAZ

Stada Arzneimittel AG manufactures pharmaceuticals. The Company produces generics (products whose patents have expired), brand-name products, and cancer therapy and other special pharmaceuticals. Stada avoids cost-intensive research on active ingredients and concentrates on multi-source products. The Company markets its products worldwide.

Hartmut RetzlaffChairman-Mgmt BoardHelmut KraftCFO/Member-Mgmt Board
Matthias WiedenfelsChief Business Develop-Mgmt BdMarkus MetzgerVP:Investor Relations
More Company Profile & Key Executives for SAZ

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil